Qiagen (NYSE:QGEN) Shares Acquired by LPL Financial LLC

LPL Financial LLC grew its stake in shares of Qiagen (NYSE:QGEN) by 2.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,240 shares of the company’s stock after purchasing an additional 432 shares during the period. LPL Financial LLC’s holdings in Qiagen were worth $768,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Geneos Wealth Management Inc. grew its holdings in Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after buying an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after acquiring an additional 526 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen during the third quarter valued at $53,000. Smartleaf Asset Management LLC grew its position in shares of Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after buying an additional 835 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock worth $68,000 after purchasing an additional 956 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on QGEN shares. Baird R W downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Robert W. Baird increased their price target on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday. Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. UBS Group dropped their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $47.83.

Qiagen Price Performance

Shares of Qiagen stock opened at $42.33 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The stock has a market capitalization of $9.41 billion, a P/E ratio of 117.87, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. The business’s 50 day simple moving average is $39.80 and its two-hundred day simple moving average is $41.71. Qiagen has a one year low of $37.63 and a one year high of $49.30.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Analysts forecast that Qiagen will post 2.26 EPS for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.